What is Denali Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Denali Therapeutics's interest expense for the
three
months ended in Dec. 2023 was $ 0.0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Denali Therapeutics's Operating Income for the
three
months ended in Dec. 2023 was $ -132.6 Mil. Denali Therapeutics's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.0 Mil.
GuruFocus does not calculate Denali Therapeutics's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Denali Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (NAS:DNLI) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Denali Therapeutics's Interest Expense for the
three
months ended in Dec. 2023 was $0.0 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-132.6 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $45.0 Mil.
Denali Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate Denali Therapeutics's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Denali Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
Denali Therapeutics (Denali Therapeutics) Business Description
Traded in Other Exchanges
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Executives
| Vicki L Sato |
director |
940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
| Carole Ho |
officer: Chief Medical Officer |
C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Ryan J. Watts |
director, officer: President and CEO |
C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Steve E. Krognes |
officer: CFO and Treasurer |
863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
| Alexander O. Schuth |
officer: COO and Secretary |
C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Marc Tessier-lavigne |
director |
1 DNA WAY, SOUTH SAN FRANCISCO CA 94080 |
| Erik Harris |
director |
60 LEVERONI COURT, NOVATO CA 94949 |
| Douglas K Bratton |
10 percent owner |
201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102 |
| Nancy Thornberry |
director |
SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036 |
| David P Schenkein |
director |
C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Biogen Inc. |
10 percent owner |
225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Biogen Ma Inc. |
10 percent owner |
225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Arch Venture Partners Viii, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Arch Venture Partners Viii, Llc |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Arch Venture Fund Viii, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Denali Therapeutics (Denali Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DNLI has been successfully added to your 